FacultyFaculty/Author Profile
Stacey L. Cohen

Stacey L. Cohen

Skadden, Arps, Slate, Meagher & Flom LLP
Counsel
New York, NY, USA


Stacey Cohen represents clients in all aspects of intellectual property litigation and arbitra- tion, with a focus on patent, trade secret, and other technology and science-based disputes and related counseling. Ms. Cohen has represented clients in the pharmaceutical, medical device, biotechnology, financial services, consumer electronics, retail, cosmetics, semi- conductor and IT industries. Ms. Cohen has particular experience in life sciences matters, including patent litigation under the Hatch-Waxman Act. She has represented clients at the district court and state court levels as well as at the appellate level before the U.S. Court of Appeals for the Federal Circuit. Ms. Cohen also has authored submissions to the Supreme Court of the U.S., including an amicus brief submitted on behalf of the American Bar Associ- ation and a petition for a Writ of Certiorari on behalf of the Innocence Project.

In addition to litigation, Ms. Cohen’s practice also includes counseling corporations on acquiring, evaluating, licensing and protecting intellectual property rights.

She is a member of the Skadden group recognized by Law360 among its 2015 “Technology Prac- tice Groups of the Year” for courtroom victories in the technology sector, and by The National Law Journal as one of the country’s leading IP practices in its “IP Hot List” for multiple years.

Ms. Cohen has been quoted by publications including Forbes, Law360, the ABA Journal and Intellectual Asset Management Blog concerning recent Supreme Court rulings on patent law.

Ms. Cohen has represented, among others, BlackBerry, Celgene, Endo Pharmaceuticals, Estee Lauder, Goldman Sachs, Hewlett-Packard, Johnson Matthey, J.P. Morgan Chase, Morgan Stanley and Mount Sinai School of Medicine.

Ms. Cohen has served as vice chair of the Biosimilars Subcommittee of the Food and Drug Committee of the American Intellectual Property Law Association.

Publications

“1 Year Later, Teva Providing Less Certainty Than Expected,” Law360, January 19, 2016

“Catching Fire: The Odds Of Patent Eligibility For Life Sciences Patents Are No Longer In Favor,” Bloomberg BNA’s Patent, Trademark & Copyright Journal, January 15, 2016

“GC Agenda: November 2015,” Practical Law, November 2015

“Spotlight on Extrinsic Evidence – What is the Anticipated Impact of Teva v Sandoz?” Intellectual Property Magazine, April 2015

“Into the Rabbit Hole: Invalidation Fallout of Alice Is Not Limited to Computer-Based Inventions,” AIPLA FDA Flash, February 2015

“How High Court Teva Ruling Will Affect Patent Litigants,” Law360, January 21, 2015

“Professional Insight: An Analysis of the First Few Decisions Following Octane Fitness — Watershed or Water Under the Bridge?” Financier Worldwide, September 2014

“Supreme Court Lowers the Bar for Attor- neys’ Fees in Patent Litigations,” Intellectual Asset Management, July/August 2014

“How Highmark and Octane Will Affect Patent Litigants,” Law360, April 30, 2014

“Joinder Under the AIA: Limited Ramifi   - tions Despite Varied Interpretations of Section 299,” Bloomberg BNA’s Patent, Trademark & Copyright Journal, November 15, 2013

“Reading Between the Lines: Implied Terms in Patent License and Settlement Agreements, NYIPLA, 2009 (Fall One-Day CLE Program)

Education

J.D., Harvard Law School, 2003

B.S., Massachusetts Institute of Technology, 2000 (Phi Beta Kappa, Order of Omega)

Bar Admissions

New York

U.S. District Courts for the Southern and Eastern Districts of New York

U.S. Court of Appeals for the Federal Circuit

U.S. Patent and Trademark Office

Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • GooglePlus
  • RSS

All Contents Copyright © 1996-2017 Practising Law Institute. Continuing Legal Education since 1933.

© 2017 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.